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Abstract
Background: Failure of the pancreatic remnant anastomosis to heal following pancreato-duodenectomy is a major
cause of significant and life-threatening complications, notably a post-operative pancreatic fistula. Recently, non-
randomized trials have shown superiority of a most intuitive anastomosis (Blumgart technique), which involves both
a duct-to-mucosa and a full-thickness pancreatic “U” stitch, in effect a mattress stitch, over a standard duct-mucosa
technique (Cattell-Warren). The aim of this study is to examine if these findings remain within a randomized setting.
Methods/Design: The PANasta trial is a randomized, double-blinded multi-center study, whose primary aim is to
assess whether a Blumgart pancreatic anastomosis (trial intervention) is superior to a Cattell-Warren pancreatic
anastomosis (control intervention), in terms of pancreatic fistula rates. Patients with suspected malignancy of the
pancreatic head, in whom a pancreato-duodenectomy is recommended, would be recruited from several UK
specialist regional centers. The hypothesis to be tested is that a Blumgart anastomosis will reduce fistula rate from
20 to 10 %. Subjects will be stratified by research site, pancreatic consistency and diameter of pancreatic duct;
giving a sample size of 253 per group. The primary outcome measure is fistula rate at the pancreatico-jejunostomy.
Secondary outcome measures are: entry into adjuvant therapy, mortality, surgical complications, non-surgical
complications, hospital stay, cancer-specific quality of life and health economic assessments. Enrolled patients will
undergo pancreatic resection and be randomized immediately prior to pancreatic reconstruction. The operation
note will only record “anastomosis constructed as per PANasta trial randomization,” thus the other members of the
trial team and patient are blinded. An inbuilt internal pilot study will assess the ability to randomize patients, while
the construction of an operative manual and review of operative photographs will maintain standardization of
techniques.
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Discussion: The PANasta trial will be the first multi-center randomized controlled trial (RCT) comparing two types
of duct-to-mucosa pancreatic anastomosis with surgical quality assurance.
Trial registration: ISRCTN52263879. Date of registration 15 January 2015.
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Background
Background and rationale for the study
Pancreato-duodenectomy as a procedure is 100 years old
[1–3]. The “Whipple” procedure, as it became known,
was refined and standardized during the 1940s to treat
head of pancreas cancer [3, 4]. Preservation of the pylorus
is now accepted [5–10]. Hence, the current “standard” re-
section preserves the pylorus with en-bloc resection of the
pancreatic head to the right of the portal vein, the extra-
hepatic bile duct, the gall bladder, the duodenum and the
proximal jejunum. Despite centralization of pancreatic
services lowering mortality to below 5 %, morbidity still
remains high, often around 50 % for all causes [11, 12].
Failure of the pancreatic anastomosis to heal is a common
culprit, with the medical literature quoting a pancreatic
leak/fistula rate of between 2 % and in excess of 20 %,
[13]. This wide range of leak/fistula rate was due partly to
a lack of a consensus definition [12]; however, recently this
has been proposed [13] and is beginning to gain support
and be quoted in the medical literature. Health economic
studies of pancreatic resection from the USA have re-
ported an average length of stay of just over 20 days with
an approximate cost of US$1000 per day [14–17]. Edge et
al. [14], showed a strong association between complica-
tions, length of hospital stay and cost. Resection without
complication on average had a hospital stay of 13 days
and cost US$30,000. Stay and cost increases proportionally
with complications, such that a minor complication in-
creased stay to 18 days (US$43,000) and a major complica-
tion to 32 days (US$90,000). Data to 2005 suggest hospital
stay is similar but that cost has increased by 63 % [18].
There are a number of techniques of pancreatic
remnant reconstruction. Stump closure is a poor op-
tion as there are excessive rates of pancreatic fistula,
pancreatitis and post-operative exocrine failure [19].
Advocates of pancreato-gastrostomy (PG) quote the
superior nature of this technique over that of a jejunal
loop, though from a poor literature base [20, 21] with
meta-analyses showing conflicting results as studies
are combined and both standardized and non-
standardized definitions of post-operative pancreatic
fistulae (POPF) are used [22, 23]. Anastomosis between
the pancreatic stump and the jejunum is regarded as the
“standard” technique by many pancreatic surgeons. There
are two main ways to perform this: invagination of the
pancreatic stump into the jejunum (pancreato-jejunostomy)
or anastomosis of the pancreatic duct to the jejunal
mucosa (pancreatico-jejunostomy), with covering par-
enchymal sutures. To date there is a lack of well-
designed and well-conducted randomized [24–27] and
non-randomized [28–32] studies, specifically looking
at these techniques, which have sufficient homogen-
eity to be compared in meta-analyses. Design issues
include the use of non-standardized definitions of POPF,
a lack of surgical quality assurance, discontinuous time
frames, no stratification for pancreatic consistency or
diameter of the pancreatic duct, lack of consideration of
the surgical learning curve and irregular use of octreo-
tide and pancreatic duct stents across the groups. Leslie
Blumgart (Memorial Sloan Kettering, New York City,
NY, USA) has devised a most intuitive anastomosis to
use in the setting as it involves both duct-to-mucosa
stitches and a full-thickness pancreatic “U” stitch, in ef-
fect a mattress stitch. This method of placing the pan-
creatic parenchymal stitches has significant mechanical
advantages over standard techniques as it in effect uses
the jejunal mucosa as a pledgelet to minimize sheering
forces of the stitches (see Fig. 1).
The rationale for this trial is that an improved method
of pancreatic anastomosis should reduce POPF, decrease
all complications, hospital stay, cost, improve patient-
reported outcomes and promote enhanced recovery
programs. Moreover, fewer POPF should enable more
patients to take advantage of adjuvant therapy with a
possible impact on longer-term survival.
Preliminary data
Since the description of the “Blumgart” anastomosis,
initial results show advantages [33, 34]. Moreover,
Kleespies et al. [35] compared a standard Cattell-
Warren pancreatico-jejunostomy with a Blumgart anas-
tomosis (BA) technique; this reduced pancreatic leak
rate from 13 to 4 % (p = 0.03) and overall complications
from 31 to 15 % (p = 0.015) in favoUr of the BA. Al-
though this study was not randomized and was single
center, it suggests the usefulness of this technique.
Objective
To compare the effectiveness of the BA pancreatico-
jejunostomy construction versus standard treatment, that
Halloran et al. Trials  (2016) 17:30 Page 2 of 14
is the Cattell-Warren anastomosis (CWA), for patients
undergoing an elective pancreatico-duodenectomy in
terms of rates of pancreatic fistula.
Trial design
The PANasta trial is a phase III multi-center study with
an internal pilot phase with blinding of patients and out-
come assessors (Fig. 2).
Methods/Design
Study setting
Screening and identification of eligible patients will take
place at the research site’s pancreatic multi-disciplinary
team (MDT) meeting; all such sites are supra-regional
referral centers for suspected pancreatic malignancy. All
patients with suspected pancreatic malignancy would
undergo standard evaluation: contrast enhanced multi-
detector computed tomography (CT) scan ± endoluminal
ultrasound (EUS), which will be discussed at the MDT.
Patients recommended for resection on the basis of a high
likelihood of a malignant lesion will be contacted and pro-
vided with a participant information sheet. Informed con-
sent will be obtained by an investigator who should
comply with applicable regulatory requirements and
should adhere to Good Clinical Practice (GCP) and to the
ethical principles that have their origin in the Declaration
of Helsinki.
It is not necessary for patients to have a histological
diagnosis of malignancy before surgery provided that the
MDT has confirmed that the lesion is of sufficient
concern to require resection [36].
Eligibility criteria
Inclusion criteria
Patients undergoing an elective pancreato-duodenectomy
for presumed malignancy; ability of the subject to
Fig. 1 Schematic of the stages of pancreatic anastomosis construction
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understand the nature or consequences of the trial; ability
to provide written informed consent and be aged 18 years
or older.
Exclusion criteria
Patients undergoing extended pancreato-duodenectomy;
left, central or total pancreatectomy; arterial resection or
multi-visceral resection; previous pancreatic resection;
surgery for known chronic pancreatitis; recruitment to
any other pancreatic resection trial (at the discretion of
the chief investigator/trial team); women of childbearing
potential, including women whose last menstrual period
was less than 1 year prior to screening; unable or
unwilling to use adequate contraception from time of
consent up to the day of surgery.
Research site criteria
All sites and participating surgeons have expertise in oper-
ating upon pancreatic malignancy at high volumes, have
confirmed experience with both methods of anastomosis
Fig. 2 Flow diagram for the PANasta trial
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and are willing to randomize patients between the two
treatment groups.
Interventions
Trial intervention
Reconstruction of the pancreatic remnant following
pancreato-duodenectomy (either Kausch-Whipple or
pylorus-preserving) using a “Blumgart” method of
pancreatico-jejunostomy.
Control intervention
Reconstruction of the pancreatic remnant following
pancreato-duodenectomy (either Kausch-Whipple or
pylorus-preserving) using a “Cattell-Warren” method of
pancreatico-jejunostomy.
Both techniques are regularly used, reported in the med-
ical literature and represent standard methods of recon-
struction of the pancreatic remnant. The standardization
of the operative techniques will be ensured by using modi-
fied methods developed with the MRC ConDuCT-II Trials
Methodology Hub [37, 38]:
1. Consensus meetings – a pre-pilot study consensus
has been reached regarding the essentials of each
anastomosis and the likely key steps, the post-
operative management of drains, pancreatic duct
stents, the use of octreotide and the timing of
operative photographs. This information will be
developed into a pilot-phase operative manual and
tested in the main phase of the trial.
2. Operative manual – following the feasibility/pilot
phase the operative manual will be reviewed and,
where applicable, adapted in accordance with the
information gained. A finalized operative manual for
each anastomosis will be formulated and contain
steps that are (a) mandatory to the construction of a
safe anastomosis; (b) prohibited for the construction
of a safe anastomosis, and (c) flexible steps where
the operating surgeon can choose a method
(please see Additional file 1).
3. Operative photographs – digital operative
photographs will be taken at the key steps during
anastomosis construction: preparation of the
pancreatic neck prior to anastomosis; insertion of
the parenchymal and duct stitches prior to knot-
tying and the completed anastomosis. Photographs
will be reviewed by the chief investigator and a
second reviewer to confirm quality and consistency
across sites.
All patients will receive an initial dose of 100 μg of
octreotide before surgery. Octreotide should then be ad-
ministered at 100 μg three times a day subcutaneously
on post-operative days 1 to 7. Surgical drains (of any
description) must be employed and should be left in
place for a minimum of 3 days after surgery. If on post-
operative day 3, the drain amylase is normal (i.e., less
than ×3 the upper amylase limit for that institution), the
drain may be removed (under the direction of the oper-
ating surgeon). The use of a pancreatic duct stent is
mandatory in all patients. Acquisition of, and upload of
operative photographs, as well as other mandatory steps,
are recorded in the case report forms (CRFs). This is a
surgical trial comparing two different methods of recon-
structing the pancreatic remnant following pancreatic head
resection. All usual medications and standard of medical
care are accepted. There is no requirement to record any
medications that are being taken by the patient.
Outcome measures
The primary outcome measure is leak/fistula rate at the
pancreatico-jejunostomy, as measured by presence/con-
tent of drain exudate and amylase content analysis within
the fluid as per the International Study Group definition:
see Table 1 [13]. Secondary outcome measures are: entry
into adjuvant therapy/clinical trials of adjuvant therapy;
mortality rate; delayed gastric empting [39]; rate of wound
infections [40]; rate of pulmonary infection; rate of post-
operative fluid collection; operation time; rate of intra-
and post-operative bleeding [41]; rate of re-operation; rate
of venous thrombo-embolism; hospital stay; generic qual-
ity of life and health economic assessments. Patients will
complete the cancer- specific questionnaire, the European
Organization for Research and Treatment of Cancer
(EORTC) QLQ-C30, themselves whereever possible at
baseline and in follow-up clinics. Postal assessments may
be made as appropriate. Complications [42] that do not
have agreed international standards for reporting will be
assessed by the Dindo and Clavien classification [43].
Timeline and recruitment
Tertiary regional centers with proven track records will
recruit into this trial. All local investigators have con-
firmed their expertise in both anastomotic techniques
and are willing to randomize with clinical equipoise. Re-
cruitment will run over 3 years with a 1-year follow-up.
The schedule of trial interventions is shown in Table 2.
An internal pilot study will run within the first 6
months. This will run in two centers initially from the
day of the trial opening and will inform whether to con-
tinue or not dependent upon actual numbers undertak-
ing enrollment as opposed to numbers of patients who
would be eligible. Following on from the pilot phase
other centers will open.
Sample size
The primary outcome is the binary measure of pancreatic
leak or no leak. Current experience suggests the present
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rate of leak is 20 % in the standard treatment; a reduction
to a 10 % rate in the trial treatment is of clinical import-
ance. A sample size of 208 patients per group would
allow a two-sided, two-sample test for binomial propor-
tions to detect a difference in proportions of 10 % (10 %
versus 20 %) with power of 80 % and significance level
of 0.05. The sample size calculation was based on an
O’Brien-Fleming two-stage design with binding futility
boundaries (SAS PROC SEQDESIGN version 9.3). Non-
compliance would occur in the event of unresectable
disease at laparotomy (estimated at 15 %) with a further
assumed loss to follow-up of 3 %, giving an overall
sample size of 253 per group (506 in total).
Randomization
Randomization will be undertaken intra-operatively by
the surgeon following pancreatic head excision and just
prior to pancreatic remnant reconstruction. Hence, the
surgeon will only randomize the participant if they feel
at complete equipoise and are happy to perform either
anastomosis. Randomization will take place via a
password-protected web-based tool called the Treatment
Allocation Randomization System (TARDIS) developed,
maintained and controlled by Liverpool Cancer Trials
Unit’s IT Department. Patients will be randomized to one
of the treatment groups in a 1:1 ratio, with the following
stratification factors: (1) research site, (2) pancreatic tex-
ture: soft versus normal/hard, and (3) pancreatic duct
diameter: 3 mm or >3 mm.
Blinding
Patients and all team members except for the surgeons
will be blinded to the intervention. In order to maintain
the blinding for the patient and other site staff, the
surgeon will not write which anastomosis has been per-
formed in the surgical notes but rather this will be re-
corded in the notes as “anastomosis constructed as per
PANasta trial randomization.” Serious adverse events
(SAEs) will be assessed blinded, and only if deemed ne-
cessary would un-blinding occur, i.e., if subjects require
life-saving surgery in a district hospital. This, however,
would be a rare event. Adverse event (AE) and SAE
reporting would follow as soon as is practical. This will
not have any impact on the endpoint assessment of the
patient.
Data management
This study is run from the Liverpool Cancer Trials Unit
(LCTU). The study CRF is the primary data collection
instrument for the study. CRF pages will be available for
sites to download from the LCTU portal: http://
www.lctu.org.uk.
Individual participant medical information obtained as
a result of this study is considered confidential and dis-
closure to third parties is prohibited. CRFs will be la-
belled with patient initials and unique trial screening
and/or trial number. Intra-operative photographs will be
transferred to the LCTU and will be identifiable by
unique trial number only. Histological slides will be
transferred to the Department of Pathology at the Royal
Liverpool University Hospital and will be identifiable by
unique trial number only. Blood samples will be trans-
ferred to the University of Liverpool GCLP laboratory
and will be identifiable by unique trial number only.
Consent forms sent to the LCTU as part of the
randomization process may contain patient identifiers
for the purpose of monitoring as described in the trial
risk assessment. Such information will be stored in
secure, locked cabinets.
Withdrawals
If voluntary withdrawal occurs, the patient will be asked
to allow continuation of scheduled evaluations, complete
an end-of-study evaluation, and be given appropriate
care under medical supervision until any AE symptoms
resolve or the subject’s condition becomes stable. Sub-
jects are free to leave the trial at any point without the
need to give reasons for their decisions. If voluntary
withdrawal occurs prior to the surgical intervention the
patient will not be randomized and no further trial data
Table 1 Post-operative pancreatic fistula: an International Study Group of Pancreatic Surgery (ISGPF) definition [14]
Grade A Grade B Grade C
Without clinical impact Clinically relevant Clinical stability may be borderline
Oral nutrition Partial/total parental/enteral nutrition Treatment in an intensive care unit in many cases
No antibiotics Peripancreatic fluid collection possible Total parental/enteral nutrition
No somatostatin analogues Abdominal pain, fever, and/or leukocytosis possible Intravenous antibiotics and somatostatin analogues necessary
No peripancreatic fluid
collection
Antibiotics and somatostatin analogues may be
necessary
Worrisome peripancreatic fluid collection that requires
percutaneous drainage
No delay in hospital
discharge
Delay in hospital discharge or readmission may be
required.
Extended hospital stay
Often associated complications and post-operative mortality
possible
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Table 2 Schedule of treatments. X demarcates the trial intervention
Visit Screening Visit1
(enrolment)
Visit 2
(Randomisation)
Post-
operative
days 4
and 6
Post
operative
days 3, 5
and 7
Visit 3
(discharge)
Visit 4
(3m FU)
Visit 5
(6m FU)
Visit 6
(12m FU)
End of Study
To assess
eligibility only
(no data to be
collected until consent)
Within 4
weeks of
surgery
Day of surgery
(Day 0)
4 and 6
days post-
surgery
3, 5 and 7
days post-
surgery
Day of
discharge
3 months
post surgery
(±4 weeks)
6 months
post surgery
(±4 weeks)
12 months
post surgery
(±4 weeks)
12 months post-
surgery (or earlier
due to other
cause)
Assessments / Procedures
Written Informed Form X1
Assessment of eligibility
criteria
X X
Suspected date of diagnosis X
Demographics (height,
weight, etc.)
X X2 X2 X2 X2
Smoking and alcohol status X
Review of Medical History
(including symptoms and
relevant tests)
X
Family Medical History X
Pregnancy Test X
Pancreatic Endocrine
Insufficiency status
X X X X X X
Diabetic status X X X X X
Adverse events X X X X X
Octreotide review3 X X X
(Day 3 & 5)
Surgical drain review X X X X X
Randomisation X
CA19-9 X
Full blood count4 X X
(Day 5 ±2 days)
X
(Day of discharge −2 days)
Serum Biochemistry5 X X
(Day 5 ±2 days)
X
(Day of discharge −2 days)
Clotting screen6 X X
(Day 5 ±2 days)
X
(Day of discharge −2 days)
Blood Sample for translational
study7
X X
(Day 5 + 2days)
Histological sample for
translational study8
X
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Table 2 Schedule of treatments. X demarcates the trial intervention (Continued)
Surgical Intervention X
Details of surgery X
Take Operative photographs X
Upload Operative Photographs9 X
Operation time X
Intra and post-operative
bleeding assessment
X X X
Post- operative fluid collection X X X X
Survival status10 X X X X X X
Delayed gastric emptying
assessment
X X
Re-operation review X X X X X
Pulmonary infection
assessment
X X
Surgical site infections
assessment
X X X X X
Venous thrombo-embolism
assessment
X X X X X
Fluid collection review (to
assess POPF)
X X X X
Length of initial hospital stay X
Re-admission review X X X
Adjuvant therapy review X X X
QoL11 X X X X X
Reason for end of study X
1. Patient consent does not need to be within 4 weeks of surgery
2. At discharge and follow up weight only to be recorded
3. Initial dose of Octreotide (100ug) to be administered on the evening before surgery (if applicable) then 100ug 3 times daily on the day of surgery and post-operative days 1 to 6
4. FBC (haemoglobin, platelets, absolute neutrophil count, white blood cell count, eosinophils, basophils, lymphocytes, monocytes) to be done pre-operatively either the evening before or morning of surgery and
post-operatively on day 5. A window of ±2 days applies to day 5 FBC only and a −2 day window applies at day of discharge
5. Serum biochemistry (sodium, potassium, calcium, urea, creatinine, eGFR, random glucose, albumin, bilirubin, alk.phosphatase, total protein, AST or ALT, GGT and CRP) to be done pre-operatively either the evening
before or morning of surgery and post-operatively on day 5. A window of ±2 days applies to day 5 serum chemistry only and a −2 day window applied at day of discharge
6. Clotting screen (PT and APTT) to be done pre-operatively either on the evening before or morning of surgery and post-operatively on day 5. A window of ±2 days applies to day 5 clotting screen only and a −2 day
window applies at day of discharge
7. Translational blood samples (10ml EDTA tube and 8.5ml SST tube) to be taken pre-operatively either on the evening before or morning of surgery and on post-operative day 5. A window of +2 days applies to the
day 5 translational blood samples
8. Diagnostic H&E slide of the pancreatic neck transection margin will be requested for all patients along with a histological report by the LCTU on a 6 monthly basis. Slides will be held for the duration of the trial and
returned at the end
9. Operative photographs should be uploaded on to the LCTU portal immediately after surgery
10. Death due to any cause must be reported by completing an End of Study Form
11. EORTC QLQ-C30 and EQ-5D and EQ-VAS to be completed
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will be collected on that patient. Patients may wish to
withdraw from the trial following the surgical interven-
tion. In such cases no further data should be collected
but data up to this time can be included in the trial if
anonymized. Patients may also wish to remove all data
and/or any samples collected up to the point of with-
drawal from the trial analysis. In these cases an End of
Study Form along with the reason for withdrawal will be
submitted to the LCTU. However, safety data that have
been sent to regulatory authorities prior to that point (e.g.,
Annual Safety Reports to Research Ethics Committee) will
not be withdrawn. For patients moving from the area,
every effort should be made for the patient to be followed-
up at another participating trial center and for this trial
center to take over responsibility for the patient or for
follow-up via the GP.
Statistical methodology
Formal interim statistical monitoring of the accumulat-
ing data will be performed at regular intervals and
reviewed by an Independent Data Monitoring and Safety
Committee (ISDMC). In addition, the design allows for
an interim analysis with possible early stopping after re-
sults for 208 patients are available. At this stage, based
on an O’Brien-Fleming two-stage design, if the standard-
ized Z value lies in the interval (−0.698, 0.698) then the
trial is stopped for acceptance of the null hypothesis of
equal proportions. If the standardized Z value is less
than −2.736 or greater than 2.736 then the trial is
stopped accepting one proportion is significantly less
than the other. Otherwise the trial continues to the final
stage where the test for the standardized Z value will have
acceptance region for the null hypothesis of (−1.934,
1.934). Values outside this region will indicate significantly
different proportions. (SAS PROC SEQDESIGN version
9.3 was used for the design.)
Early stopping rule: the first 6 months of the study will
be run as a feasibility/pilot study with a decision,
whether to continue or not, made at that point. Two
sites will be opened initially for this feasibility/pilot
phase. The decision whether to continue or not will be
based on the number found to be eligible across the two
sites, the number enrolled, the number randomized and
the number who took up the randomization. If the num-
ber enrolled at 6 months is less than 40 patients, then a
decision will be made as to whether to continue the trial
or not. If the recruitment rate is acceptable then the
other sites will be opened, with an expected number of
patients at 12 months of 137 across all sites.
The trial will be analyzed and reported following the
Consolidated Standards of Reporting Trials (CONSORT)
guidelines [44, 45]. All statistical analyses will be on an
intention-to-treat basis. Missing data, which are antici-
pated to mainly affect the quality of life outcome
measure, will be handled by considering the robustness
of the complete case analysis to sensitivity analyses using
different imputation assumptions informed by data col-
lected on reasons for missing data. Continuous variables
will be summarized by descriptive statistics (mean,
standard deviation, minimum, median and maximum)
and frequency tables will be provided for categorical
data. The two-sided, two-sample test for binomial pro-
portions will be used to test for a difference in the prob-
abilities of leak/fistula occurrence between the two arms.
Sensitivity analysis will be performed using the continuity-
corrected Cochran-Mantel-Haenszel (CMH) test calcu-
lated over the recruiting centers. Logistic regression will
be used to investigate the variation in these probabilities
by center. The secondary endpoints will be analyzed using
summary statistics, CMH tests, logistic regression, analysis
of variance and multi-variate methods as appropriate. As
the two procedures are standard practice, a formal analysis
of the primary endpoint only will be undertaken when half
the patients have been recruited. Quality of life measure-
ments will be assessed over time and comparisons made
between treatment groups using longitudinal analysis with
appropriate recognition for informative dropout.
Trial oversight committees
Trial Management Group (TMG)
This comprises the chief investigator, other lead investi-
gators (clinical and non-clinical) and members of the
LCTU. The TMG will be responsible for the day-to-day
running and management of the trial and will meet ap-
proximately three times a year.
Trial Steering Committee (TSC)
The Trial Steering Committee will consist of the TMG
plus independent members, two co-investigators and a
patient representative. The TSC will provide overall
supervision for the trial and provide advice through its
independent chairman. The ultimate decision for the
continuation of the trial lies with the TSC.
Independent Data and Safety Monitoring Committee
(IDSMC)
The Independent Data and Safety Monitoring Committee
(IDSMC) will be responsible for reviewing and assessing
recruitment, interim monitoring of safety and effective-
ness, trial conduct and external data. The ISDMC will first
convene prior to trial opening and will then define fre-
quency of subsequent meetings (at least annually). The
ISDMC will provide a recommendation to the TSC con-
cerning the continuation of the study.
Trial organization and monitoring
This trial is sponsored by the University of Liverpool
(UoL000732) and is co-ordinated through the LCTU.
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This study has been funded by Cancer Research UK
(CRUKE/13/019). Site monitoring is conducted to ensure
protection of patients participating in the trial, trial proce-
dures, laboratory, trial intervention administration, and
data collection processes are of high quality and meet
sponsor and, when appropriate, regulatory requirements.
The trial will be audited periodically by the University of
Liverpool and the LCTU quality assurance manager. A
risk assessment in accordance with the MRC/DH/MHRA
Project on Risk-adapted Approaches to the Management of
Clinic Trials of Investigational Medicinal Products (http://
www.mhra.gov.uk/home/groups/l-ctu/documents/websiter-
esources/con111784.pdf) has been undertaken for the
PANasta trial. As this is a surgical intervention trial of two
standard techniques of reconstructing the pancreatic
remnant the risk assessment resulted in a trial category of
Type A, and thus the trial is considered to be low-risk.
Safety and adverse event reporting
Adverse event (AE)
Any untoward medical occurrence (i.e., any unfavorable
or unintended sign including abnormal laboratory re-
sults), symptom or disease in a research participant to
whom a medicinal-/-clinical investigation has been ad-
ministered, including occurrences which are not neces-
sarily caused by or related to that product-/investigation.
Serious adverse event (SAE)
Any AE is classified as serious if it:
1. Results in death
2. Is life-threatening (subject at immediate risk of
death)
3. Requires in-patient hospitalization or prolongation
of existing hospitalization
4. Results in persistent or significant disability or
incapacity, or
5. Consists of a congenital anomaly or birth defect
6. Important medical events that may not be
immediately life-threatening or result in death or
hospitalization but may jeopardize the patient or
may require intervention to prevent one of the other
outcomes listed in the definition above should also
be considered serious
All AEs that occur from time of surgery up to the
point at which a patient starts adjuvant therapy should
be reported. The assignment of the severity or grading
should be made by the investigator who is responsible
for the care of the participant. Regardless of the classifi-
cation of an AE as serious or not, its severity must be
assessed according to medical criteria (Table 3). The as-
signment of causality will be assessed according to the
definitions outlined in Table 4.
The expected events for this trial along with reporting
obligations are detailed in Table 5. Expected events (pri-
mary and secondary endpoints) for the trial are exempt
from SAE reporting unless they are classified as life-
threatening or result in death (grades 4/5). Events that
are exempt from SAE reporting should be reported in
the relevant sections of the CRFs and do not need to be
reported as an SAE. All other events that meet the cri-
teria for serious must be reported as an SAE and those
that do not feature as expected should be classified as
unexpected. An AE where the causal relationship to
the study procedure is assessed by the investigator as
“possible,” “probable,” or “highly probable,” is graded
as serious and unexpected is subject to expedited
reporting to the Main Research Ethics Committee
(MREC). This is the responsibility of the LCTU.
Ethical considerations
This study has been submitted to the National Research
Ethics Service, Committee North West – Greater
Table 3 Definitions of severity
Definition of severity
of adverse event
Grade Description
1. Mild Grade 1 Does not interfere with patient’s usual
function (awareness of symptoms or
signs, but easily tolerated (acceptable)
2. Moderate Grade 2 Interferes to some extent with patient’s
usual function (enough discomfort to
interfere with usual activity (disturbing)
3. Severe Grade 3 Interferes significantly with patient’s
usual function (incapacity to work or to
do usual activities (unacceptable)
4. Life-threatening Grade 4 Results in risk of death, organ damage,
or permanent disability (unacceptable)
5. Death Grade 5 Results in death (unacceptable)
Table 4 Definitions of causality
Relationship Description
None There is no evidence of any causal relationship. N.B. an
alternative cause for the AE should be given
Unlikely There is little evidence to suggest there is a causal
relationship (e.g., the event did not occur within a
reasonable time after the trial procedure). There is
another reasonable explanation for the event (e.g., the
participant’s clinical condition, other concomitant
treatment)
Possibly There is some evidence to suggest a causal relationship
(e.g., because the event occurs within a reasonable
time after the trial procedure). However, the influence
of other factors may have contributed to the event
(e.g., chemotherapy or other concomitant treatments)
Probably There is evidence to suggest a causal relationship and
the influence of other factors is unlikely
Highly
probable
There is clear evidence to suggest a causal relationship
and other possible contributing factors can be ruled out
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Manchester South (Ref. 14/NW/1393) and received a
favorable opinion on 22 December 2014.
Protocol amendments
Version 1 (22 September 2014), version 2 (6 October 2014),
version 3 (10 October 2014), version 4 (5 January 2015)
and version 5 (22 July 2015).
Translational research
In addition to the routine blood assessments, transla-
tional blood samples will be taken either the evening be-
fore or the morning of surgery and then again at post-
operative day 5. Sample collection kits will be sent to all
participating sites and the samples collected and stored
to GCP standard in Liverpool. These samples will be
used at a future date to evaluate individual cytokine
levels correlated to outcome of each anastomosis. In
addition the hematoxylin and eosin slide of the trans-
ected pancreatic neck (which is standard pathological
reporting) will be assessed for amount of fibrosis and
vascular architecture and again correlated to each
anastomosis.
Indemnity
PANasta is sponsored by the University of Liverpool and
co-ordinated by the LCTU in the University of Liver-
pool. The University of Liverpool does not hold insur-
ance against claims for compensation for injury caused
by participation in a clinical trial and cannot offer any
indemnity. However, in terms of liability, NHS trust and
non-trust hospitals have a duty of care to patients
treated, whether or not the patient is taking part in a
clinical trial, and they are legally liable for the negligent
acts and omission of their employees. Compensation is,
therefore, available in the event of clinical negligence be-
ing proven.
Dissemination
The results from different centers will be analyzed to-
gether and published as soon as possible. The TMG will
form the basis of the Writing Committee and will advise
on the nature of publications.
Discussion
Pancreato-duodenectomy for a tumor in the head of the
pancreas is now a standardized procedure. Although
centralization of services has driven mortality down, the
morbidity, if honestly reported, coupled with sensitive def-
initions and active, prospective ascertainment of compli-
cations, is around 50 %. Although some complications are
modest, failure of the pancreatic remnant anastomosis to
heal is a major cause for a number of significant and life-
threatening complications. In addition, pancreatic anasto-
motic breakdown causing a POPF is a cause of increased
length of stay and cost to the healthcare provider, notwith-
standing misery for the patient and the potential of de-
layed adjuvant chemotherapy, until the fistula is healed.
There are many options available to surgeons when
considering pancreatic anastomosis; however, this has
muddied the waters rather than provided clear evidence.
Table 5 Expected and unexpected events for serious adverse event (SAE) reporting
Expectedness Event Grade 3 and below Grade 4 and above
Report as
SAE
Subject to expedite
reporting
Report as
SAE
Subject to expedite
reporting
Expected Pancreatic fistula (graded as A, B or C) No No Yes No
Delayed gastric emptying (graded as A, B, or C) No No Yes No
Wound infections No No Yes No
Pulmonary Infection No No Yes No
Post-operative fluid collection No No Yes No
Intra- and post-operative bleeding No No Yes No
Re-operation No No Yes No
Venous thromboembolism No No Yes No
Interventional drainage procedures No No Yes No
Extended hospital stay due to delayed surgery No No Yes No
Surgical complication related hospital stay No No Yes No
New post-operative pancreatic exocrine and or endocrine
failure
Yes No Yes No
Unexpected Any other serious event deemed to be unrelated to the
surgical intervention
Yes No Yes No
Any other serious event deemed to be related to the
surgical intervention
Yes Yes Yes Yes
Halloran et al. Trials  (2016) 17:30 Page 11 of 14
Thus, to date there are neither randomized nor non-
randomized trials of any of the techniques [20–33];
whether comparing reconstruction to the stomach ver-
sus a jejunal loop, or duct to mucosa versus invagination
of jejunal limbs, to adequately construct meta-analyses
that inform the medical literature. Those that are published,
are littered with homogeneity and bias relating to: non-
standardized definition of POPF, non-standardized tech-
nique, no attempt at internal quality control, discontinuous
time frames, no stratification of soft/hard pancreatic
consistency or diameter of pancreatic duct, unfamiliarity
with technique at some centers and irregular use of
octreotide and pancreatic duct stents.
The PANasta trial (logo Fig. 3) is unique in that it will
compare two different methods of pancreatic duct-to-
mucosa pancreatico-jejunostomy: Blumgart versus Cattell-
Warren anastomoses. Hence, the PANasta trial aims to
identify an improved method of pancreatic anastomosis
which should reduce POPF, decrease all complications,
hospital stay, cost and promote enhanced recovery pro-
grams. Moreover, fewer POPF should enable more
patients to take advantage of adjuvant therapy.
This study is ambitiously intending to randomize over
500 patients undergoing pancreatic surgery. These num-
bers are powered to detect a 10 % absolute point reduc-
tion in the primary endpoint of POPF – which is a
relevant difference in surgical trials. Included is a gener-
ous dropout rate and account is also taken of patients
who are not randomized if unresectable disease is en-
countered at laparotomy. Furthermore, randomization
will be undertaken following resection, just prior to
pancreatic anastomosis; therefore, maximising surgeon
equipoise. One of the prime reasons that the current
medical literature base on pancreatic anastomosis is so
poor is the lack of operative standardization not only be-
tween individuals but also between centers. In order to
diminish this as much as is possible a number of safe-
guards are built into this study: notably incorporation of
a feasibility pilot study within the first 6 months; a pre-
pilot consensus meeting; formulation of an operative
manual and operative photographs.
The internal pilot will run in two centers initially and
will evaluate in step-wise fashion: (1) the number of pa-
tients eligible at each site; (2) the number of patients
consented; (3) the number of patients randomized; and
finally (4) the number of patients who took up the
randomization. This will inform us of the real figures for
stopping this trial for futility in recruitment. In addition,
an interim analysis will be undertaken once 208 patients
have been randomized.
The pre-pilot consensus meeting was attended by the
research site principal investigators (PIs), who agreed
that the use of octreotide, pancreatic duct stents and
post-operative drains were to be used in all patients.
The steps of each anastomosis were discussed and
agreed. The adherence to these steps will be reviewed at
the end of the internal pilot phase and the manual and
protocol modified as necessary.
An operative manual (Additional file 1) has been con-
structed and will be followed during the pilot phase of
this study. The investigators will meet following the pilot
study, prior to the main study opening to re-evaluate
which steps are mandatory, prohibited or flexible to the
construction of a safe anastomosis. Furthermore, during
both the pilot and full trial operative photographs will be
taken of the three key phases of each anastomosis. These
will be continuously monitored and any recurrent de-
fects will be reported to the ISDMC. Both the operative
manual and operative photographs will form the quality
control and standardization of the trial beyond the pilot
phase into the full trial.
In conclusion, the PANasta trial will be the first multi-
center randomized controlled trial (RCT) to compare
two methods of pancreatico-jejunostomy (Blumgart ver-
sus Cattell-Warren) to assess the impact on pancreatic
fistula and leak. This study is, therefore, planned to pro-
vide important evidence to inform health policy and
clinical decision-making relevant to patients undergoing
pancreatico-duodenectomy for presumed cancer of the
pancreas.
Trial status
Open and recruiting: “green light” 23 April 2015; first
patient enrolled 29 April 2015 and first patient random-
ized 5 May 2015.
Additional file
Additional file 1: PANasta operative manual. (PDF 520 kb)
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